scholarly journals Redesign of the Clinical Pharmacy Practice Model in a Tertiary Academic Hospital in Medellín, Colombia

2017 ◽  
Vol 70 (3) ◽  
Author(s):  
Juan Pablo Botero Aguirre ◽  
Andrés Felipe Valencia Quintero ◽  
Elkyn Johan Granados Vega

-

2015 ◽  
Vol 18 (3) ◽  
pp. A260
Author(s):  
S. Pinto ◽  
T.J. Hastings ◽  
R Bechtol ◽  
Vaidya ◽  
S. Khuder

2016 ◽  
Vol 36 (11) ◽  
pp. e195-e197 ◽  
Author(s):  
Lisa M. Potter ◽  
Eric M. Tichy ◽  
Timothy A. Horwedel ◽  
Michael A. Shullo ◽  
Christopher R. Ensor ◽  
...  

2015 ◽  
Vol 5 (1) ◽  
pp. 50-56
Author(s):  
Monica Zolezzi ◽  
Ingo Gottstein ◽  
Benjamin Nilsson

Introduction: Integrated, patient-centered clinical pharmacy services have been shown to improve patient outcomes in a variety of settings, including mental health. In this article, we describe and report the impact of a restructured clinical practice model that incorporated direct patient care by pharmacists implemented at a psychiatric facility in Edmonton, Canada. The purpose of redesigning the clinical pharmacy program was to deliver proactive pharmacist care through integrated clinical pharmacy services and to better align pharmacists' activities with those that have been reported to have a positive impact on patient outcomes. Methods: Pharmacists' documentation notes in medical records for patients admitted and discharged from the hospital at four different time periods were reviewed. For each time period, the number, type, and documentation rate were measured and compared using a Student t test with correction for unequal variances. Significant change was defined as P < .05. Documentation rates were also compared for short-stay versus long-stay patients. Results: A consistent and statistically significant increase was found in pharmacists' clinical notes per chart from 0.15 to 1.5 (P < .001) after implementation of the redesigned clinical practice model. The proportion of clinical notes also increased from 22% in the preimplementation period to up to 68% in the current period. This indicates that pharmacists were spending proportionally more time on proactive versus reactive care. Documentation rates also increased regardless of the patients' length of stay. Discussion: The redesigned clinical practice model enabled a successful transition of the pharmacists' role, from being predominantly reactive to becoming more proactive and integrated.


2016 ◽  
Vol 36 (5) ◽  
pp. e40-e49 ◽  
Author(s):  
Judith Jacobi ◽  
Shaunta' Ray ◽  
Ilya Danelich ◽  
Elizabeth Dodds Ashley ◽  
Stephen Eckel ◽  
...  

Author(s):  
Asad E Patanwala ◽  
Sujita W Narayan ◽  
Curtis E Haas ◽  
Ivo Abraham ◽  
Arthur Sanders ◽  
...  

Abstract Disclaimer In an effort to expedite the publication of articles related to the COVID-19 pandemic, AJHP is posting these manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time. Purpose Cost-avoidance studies of pharmacist interventions are common and often the first type of study conducted by investigators to quantify the economic impact of clinical pharmacy services. The purpose of this primer is to provide guidance for conducting cost-avoidance studies pertaining to clinical pharmacy practice. Summary Cost-avoidance studies represent a paradigm conceptually different from traditional pharmacoeconomic analysis. A cost-avoidance study reports on cost savings from a given intervention, where the savings is estimated based on a counterfactual scenario. Investigators need to determine what specifically would have happened to the patient if the intervention did not occur. This assessment can be fundamentally flawed, depending on underlying assumptions regarding the pharmacists’ action and the patient trajectory. It requires careful identification of the potential consequence of nonaction, as well as probability and cost assessment. Given the uncertainty of assumptions, sensitivity analyses should be performed. A step-by-step methodology, formula for calculations, and best practice guidance is provided. Conclusions Cost-avoidance studies focused on pharmacist interventions should be considered low-level evidence. These studies are acceptable to provide pilot data for the planning of future clinical trials. The guidance provided in this article should be followed to improve the quality and validity of such investigations.


2004 ◽  
Vol 34 (4) ◽  
pp. 258-259 ◽  
Author(s):  
Penny Thornton

2007 ◽  
Vol 15 (4) ◽  
pp. 331-337 ◽  
Author(s):  
Lynne Emmerton ◽  
Tracey Bessell ◽  
Jennifer Marriott ◽  
Lisa Nissen ◽  
Laura Dean

Sign in / Sign up

Export Citation Format

Share Document